Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2014 Apr 10:14:73.
doi: 10.1186/1471-230X-14-73.

KRAS mutations: variable incidences in a Brazilian cohort of 8,234 metastatic colorectal cancer patients

Affiliations

KRAS mutations: variable incidences in a Brazilian cohort of 8,234 metastatic colorectal cancer patients

Carlos Gil Ferreira et al. BMC Gastroenterol. .

Abstract

Background: KRAS mutations are frequently found in colorectal cancer (CRC) indicating the importance of its genotyping in the study of the molecular mechanisms behind this disease. Although major advances have occurred over the past decade, there are still important gaps in our understanding of CRC carcinogenesis, particularly whether sex-linked factors play any role.

Methods: The profile of KRAS mutations in the Brazilian population was analyzed by conducting direct sequencing of KRAS codons 12 and 13 belonging to 8,234 metastatic CRC patient samples. DNA was extracted from paraffin-embedded tissue, exon 1 was amplified by PCR and submitted to direct sequencing. The data obtained was analysed comparing different geographical regions, gender and age.

Results: The median age was 59 years and the overall percentage of wild-type and mutated KRAS was 62.8% and 31.9%, respectively. Interestingly, different percentages of mutated KRAS patients were observed between male and female patients (32.5% versus 34.8%, respectively; p = 0.03). KRAS Gly12Asp mutation was the most prevalent for both genders and for most regions, with the exception of the North where Gly12Val was the most frequent mutation found.

Conclusions: To the best of our knowledge this is one of the largest cohorts of KRAS genotyping in CRC patients and the largest to indicate a higher incidence of KRAS mutation in females compared to males in Brazil. Nevertheless, further research is required to better address the impact of gender differences in colorectal cancer.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Overall percentage of mutant versus wild-type KRAS cases. A total of 8,234 samples were pooled for analysis and 437 tests presented an inconclusive KRAS diagnostic.
Figure 2
Figure 2
Percentage of mutant KRAS cases according to sex and age. Variables such as gender and age were analysed and the age ranges for both sexes were: ≤40 (p = 0.27), 40–50 (p = 0.02), 50–60 (p = 0.02), 60–70 (p = 0.47) and ≥70 (p = 0.73).

References

    1. Ely S. Personalized medicine: individualized care of cancer patients. Transl Res. 2009;154(6):303–308. doi: 10.1016/j.trsl.2009.08.001. - DOI - PubMed
    1. Winer E, Gralow J, Diller L, Karlan B, Loehrer P, Pierce L, Demetri G, Ganz P, Kramer B, Kris M, Markman M, Mayer R, Pfister D, Raghavan D, Ramsey S, Reaman G, Sandler H, Sawaya R, Schuchter L, Sweetenham J, Vahdat L, Schilsky RL. Clinical cancer advances 2008: major research advances in cancer treatment, prevention, and screening–a report from the American Society of Clinical Oncology. J Clin. 2009;27(5):812–826. doi: 10.1200/JCO.2008.21.2134. - DOI - PMC - PubMed
    1. Karapetis CS, Khambata-Ford S, Jonker DJ, O’Callaghan CJ, Tu D, Tebbutt NC, Simes RJ, Chalchal H, Shapiro JD, Robitaille S, Price TJ, Shepherd L, Au HJ, Langer C, Moore MJ, Zalcberg JR. K-ras mutations and benefit from cetuximab in advanced colorectal cancer. N Engl J Med. 2008;359(17):1757–1765. doi: 10.1056/NEJMoa0804385. - DOI - PubMed
    1. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2012. CA Cancer J Clin. 2012;62(1):10–29. doi: 10.3322/caac.20138. - DOI - PubMed
    1. Palomba G, Colombino M, Contu A, Massidda B, Baldino G, Pazzola A, Ionta M, Capelli F, Trova V, Sedda T, Sanna G, Tanda F, Budroni M, Palmieri G, Cossu A, Contu M, Cuccu A, Farris A, Macciò A, Mameli G, Olmeo N, Ortu S, Petretto E, Pusceddu V, Virdis L. Sardinian Translational Oncology Group (STOG) Prevalence of KRAS, BRAF, and PIK3CA somatic mutations in patients with colorectal carcinoma may vary in the same population: clues from Sardinia. J Transl Med. 2012;10:178. doi: 10.1186/1479-5876-10-178. - DOI - PMC - PubMed

Publication types